Okta To Rally More Than 20%? Here Are 10 Top Analyst Forecasts For Thursday
Key takeaways
- Analysts are broadly upbeat, lifting price targets across tech and biotech, with Okta’s target jump to $170 indicating strong upside potential.
- Okta target: $170 (up 36%)
- Moderna target: $89 (up 128%)
- Merck target: $179 (up 54%)
What happened
Analysts across the market have revised their price targets for several high‑profile stocks, most notably raising Okta Inc (NASDAQ: OKTA) from $125 to $170, Moderna Inc (NASDAQ: MRNA) from $39 to $89, and Merck & Co Inc (NYSE: MRK) from $116 to $179. Other moves include Progressive Corp (NYSE: PGR) target to $250, Ultragenyx Pharmaceutical (NASDAQ: RARE) to $103, Analog Devices (NASDAQ: ADI) to $450, Glaukos Corp (NYSE: GKOS) to $202, NIQ Global Intelligence (NYSE: NIQ) to $21, and Rubrik Inc…
Why it matters
These upward revisions signal growing confidence in the companies’ growth prospects and earnings potential, which can lift investor sentiment and support higher share prices. For Okta, the jump to $170 reflects expectations of continued expansion in identity‑as‑a‑service, while Moderna’s $89 target underscores…
Short-term and longer-term
Short-term. Short‑term traders should watch Okta’s price action around the new $170 target, as the upgrade could trigger a rally.
Longer-term. Long‑term investors may view the upgraded targets as confirmation of solid growth trajectories, especially for Okta’s identity platform and Moderna’s mRNA technology.